Letters, Testimony & Comments

BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.

The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for…

BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal

BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.

Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.

Frequently Asked Questions Document

BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.

Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.

BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…

BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.